Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review

Müller, Volkmar; Bartsch, Rupert; Lin, Nancy U.; Montemurro, Filippo; Pegram, Mark D.; Tolaney, Sara M.

doi:10.1016/j.ctrv.2023.102527

Cited by 10 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yet, the presence of a drug with efficacy both within the brain and beyond could profoundly transform the multidisciplinary care of patients with HER2-positive metastatic breast cancer and brain metastases. Implementing a personalized treatment strategy that involve surgery, radiotherapy, and systemic treatments based on individual patient characteristics has the potential to enhance prognosis and quality of life [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”

Conte,

Ciruelos,

Curigliano

et al. 2024

The Breast

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…However, the current landscape compels to address the unmet challenges arising in the wake of disease progression. Particularly, the threat of brain metastases emerges as a critical concern, necessitating a move towards more tailored interventions [ [6] , [7] , [8] ].…”

Section: Introductionmentioning

confidence: 99%

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”

Conte,

Ciruelos,

Curigliano

et al. 2024

The Breast

View full text Add to dashboard Cite

“…Clinical categorization of breast cancer into Luminal A, Luminal B, HER2 overexpression, and triple-negative subtypes, based on ER, PR, HER2, and Ki67, has guided therapeutic decisions [ 4 , 5 ]. However, breast cancer's complexity and heterogeneity across individuals have posed significant challenges [ 6 , 7 ]. Currently, surgery, radiation, and endocrine therapy constitute the mainstay treatments for BRCA.…”

Section: Introductionmentioning

confidence: 99%

Spatial and single-cell explorations uncover prognostic significance and immunological functions of mitochondrial calcium uniporter in breast cancer

Li,

Tzeng,

Hsiao

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

The mitochondrial calcium uniporter (MCU) is a transmembrane protein facilitating the entry of calcium ions into mitochondria from the cell cytosol. Maintaining calcium balance is crucial for enhancing cellular energy supply and regulating cell death. The interplay of calcium balance through MCU and the sodium-calcium exchanger is known, but its regulation in the breast cancer tumor microenvironment remains elusive. Further investigations are warranted to explore MCU’s potential in BRCA clinical pathology, tumor immune microenvironment, and precision oncology. Our study, employing a multi-omics approach, identifies MCU as an independent diagnostic biomarker for breast cancer (BRCA), correlated with advanced clinical status and poor overall survival. Utilizing public datasets from GEO and TCGA, we discern differentially expressed genes in BRCA and examine their associations with immune gene expression, overall survival, tumor stage, gene mutation status, and infiltrating immune cells. Spatial transcriptomics is employed to investigate MCU gene expression in various regions of BRCA, while spatial transcriptomics and single-cell RNA-sequencing methods explore the correlation between MCUs and immune cells. Our findings are validated through the analysis of 59 BRCA patient samples, utilizing immunohistochemistry and bioinformatics to examine the relationship between MCU expression, clinicopathological features, and prognosis. The study uncovers the expression of key gene regulators in BRCA associated with genetic variations, deletions, and the tumor microenvironment. Mutations in these regulators positively correlate with different immune cells in six immune datasets, playing a pivotal role in immune cell infiltration in BRCA. Notably, high MCU performance is linked to CD8 + T cells infiltration in BRCA. Furthermore, pharmacogenomic analysis of BRCA cell lines indicates that MCU inactivation is associated with increased sensitivity to specific small molecule drugs. Our findings suggest that MCU alterations may be linked to BRCA progression, unveiling new diagnostic and prognostic implications for MCU in BRCA. The study underscores MCU's role in the tumor immune microenvironment and cell cycle progression, positioning it as a potential tool for BRCA precision medicine and drug screening.

show abstract

“…agentes dirigidos contra HER2 que son clínicamente eficaces: trastuzumab, pertuzumab, margetuximab, trastuzumab emtansina (T-DM1), trastuzumab deruxtecan (T-DXd), tucatinib, lapatinib, neratinib y pirotinib(14). En concreto, los avances en el tratamiento adyuvante de la enfermedad HER2+ han reducido el riesgo de recidiva sistémica, pero con escaso impacto en el riesgo de recaída en SNC.…”

unclassified

Advances in the Management of Central Nervous System Metastases from Breast Cancer

González¹,

Buznego²,

Martín³

2023

Rev Cancer

View full text Add to dashboard Cite

El cáncer de mama es la segunda causa más frecuente de metástasis cerebrales. Su incidencia ha aumentado en los últimos años, especialmente en las pacientes con tumores de mama triple negativo o HER2 positivo. La supervivencia varía ampliamente en función de una serie de factores pronósticos. El abordaje de las metástasis cerebrales en cáncer de mama diseminado requiere un manejo multidisciplinar, con cambios en los últimos años, que conducen a un mayor empleo del tratamiento sistémico y a la radioterapia estereotáctica (SRS). Disponemos de resultados especialmente prometedores con nuevos fármacos anti-HER2 y con conjugados anti cuerpo-fármaco (ADC). A pesar de la mejoría en los tratamientos, las metástasis cerebrales en cáncer de mama siguen siendo un reto terapéutico. Los esfuerzos se centran en su prevención, su diagnóstico precoz y en la búsqueda de tratamientos eficaces.PALABRAS CLAVE: Cáncer de mama avanzado. Metástasis cerebrales.Sistema nervioso central (SNC).

show abstract

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review

Cited by 10 publications

References 82 publications

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”

Spatial and single-cell explorations uncover prognostic significance and immunological functions of mitochondrial calcium uniporter in breast cancer

Advances in the Management of Central Nervous System Metastases from Breast Cancer

Contact Info

Product

Resources

About